Bing Wang1,2,3,4, Renee Santoreneos5, Hossein Afzali6, Lynne Giles6, Helen Marshall7,8,6,9. 1. Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia. bing.wang@adelaide.edu.au. 2. Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia. bing.wang@adelaide.edu.au. 3. School of Public Health, The University of Adelaide, Adelaide, SA, Australia. bing.wang@adelaide.edu.au. 4. Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, North Adelaide, SA, Australia. bing.wang@adelaide.edu.au. 5. Royal Adelaide Hospital, Adelaide, SA, Australia. 6. School of Public Health, The University of Adelaide, Adelaide, SA, Australia. 7. Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia. 8. Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia. 9. Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, North Adelaide, SA, Australia.
Abstract
BACKGROUND: Invasive meningococcal disease remains a public health concern because of its rapid onset and significant risk of death and long-term disability. New meningococcal serogroup B and combination serogroup ACWY vaccines are being considered for publicly funded immunization programs in many countries. Contemporary costing data associated with invasive meningococcal disease are required to inform cost-effectiveness analyses. OBJECTIVE: The objective of this study was to estimate costs and resource utilization associated with acute infection and the long-term care of invasive meningococcal disease. DATA SOURCES AND METHODS: PubMed, EMBASE, The Cochrane Library, health economic databases, and electronically available conference abstracts were searched. Studies reporting any costs associated with acute infection and long-term sequelae of invasive meningococcal disease in English were included. All costs were converted into purchasing power parity-adjusted estimates [international dollars (I$)] using the Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre cost converter. RESULTS: Fourteen studies met our eligibility criteria and were included. The mean costs of acute admission ranged from I$1629 to I$50,796, with an incremental cost of I$16,378. The mean length of hospital stay was reported to be 6-18 days in multiple studies. The average costs reported for readmissions ranged from I$7905 to I$15,908. Key variables such as the presence of sequelae were associated with higher hospitalization costs and longer inpatient stay. No studies estimated direct non-healthcare costs and productivity loss. Ten studies reported only unadjusted mean values without using appropriate statistical methods for adjustment. CONCLUSIONS: Invasive meningococcal disease can result in substantial costs to healthcare systems. However, costing data on long-term follow-up and indirect costs used to populate health economic models are lacking.
BACKGROUND:Invasive meningococcal disease remains a public health concern because of its rapid onset and significant risk of death and long-term disability. New meningococcal serogroup B and combination serogroup ACWY vaccines are being considered for publicly funded immunization programs in many countries. Contemporary costing data associated with invasive meningococcal disease are required to inform cost-effectiveness analyses. OBJECTIVE: The objective of this study was to estimate costs and resource utilization associated with acute infection and the long-term care of invasive meningococcal disease. DATA SOURCES AND METHODS: PubMed, EMBASE, The Cochrane Library, health economic databases, and electronically available conference abstracts were searched. Studies reporting any costs associated with acute infection and long-term sequelae of invasive meningococcal disease in English were included. All costs were converted into purchasing power parity-adjusted estimates [international dollars (I$)] using the Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre cost converter. RESULTS: Fourteen studies met our eligibility criteria and were included. The mean costs of acute admission ranged from I$1629 to I$50,796, with an incremental cost of I$16,378. The mean length of hospital stay was reported to be 6-18 days in multiple studies. The average costs reported for readmissions ranged from I$7905 to I$15,908. Key variables such as the presence of sequelae were associated with higher hospitalization costs and longer inpatient stay. No studies estimated direct non-healthcare costs and productivity loss. Ten studies reported only unadjusted mean values without using appropriate statistical methods for adjustment. CONCLUSIONS:Invasive meningococcal disease can result in substantial costs to healthcare systems. However, costing data on long-term follow-up and indirect costs used to populate health economic models are lacking.
Authors: Julie A Bettinger; David W Scheifele; Nicole Le Saux; Scott A Halperin; Wendy Vaudry; Raymond Tsang Journal: Pediatr Infect Dis J Date: 2013-01 Impact factor: 2.129
Authors: Ray Borrow; Pedro Alarcón; Josefina Carlos; Dominique A Caugant; Hannah Christensen; Roberto Debbag; Philippe De Wals; Gabriela Echániz-Aviles; Jamie Findlow; Chris Head; Daphne Holt; Hajime Kamiya; Samir K Saha; Sergey Sidorenko; Muhamed-Kheir Taha; Caroline Trotter; Julio A Vázquez Moreno; Anne von Gottberg; Marco A P Sáfadi Journal: Expert Rev Vaccines Date: 2016-11-22 Impact factor: 5.217
Authors: Osama I Alwassil; Sandeep Chandrashekharappa; Susanta K Nayak; Katharigatta N Venugopala Journal: PLoS One Date: 2019-10-16 Impact factor: 3.240
Authors: Helen S Marshall; Prabha H Andraweera; Bing Wang; Mark McMillan; Ann P Koehler; Noel Lally; Sara Almond; Emma Denehy; Michele A'Houre; Lynne C Giles; Louise Flood Journal: Hum Vaccin Immunother Date: 2021-01-11 Impact factor: 3.452
Authors: Helen S Marshall; Prabha H Andraweera; James Ward; John Kaldor; Ross Andrews; Kristine Macartney; Peter Richmond; Vicki Krause; Ann Koehler; David Whiley; Lynne Giles; Rosalind Webby; Heather D'Antoine; Jonathan Karnon; Rob Baird; Andrew Lawrence; Helen Petousis-Harris; Philippe De Wals; Belinda Greenwood-Smith; Michael Binks; Lisa Whop Journal: Vaccines (Basel) Date: 2022-02-16
Authors: Sandra Guedes; Isabelle Bertrand-Gerentes; Keith Evans; Florence Coste; Philipp Oster Journal: BMC Public Health Date: 2022-02-23 Impact factor: 3.295
Authors: Helen Marshall; Mark McMillan; Bing Wang; Robert Booy; Hossein Afzali; Jim Buttery; Christopher C Blyth; Peter Richmond; David Shaw; David Gordon; Belinda Barton Journal: BMJ Open Date: 2019-12-29 Impact factor: 2.692
Authors: Stefan Walter; Ruth Gil-Prieto; Mario Gil-Conesa; Gil Rodriguez-Caravaca; Jesús San Román; Angel Gil de Miguel Journal: BMC Infect Dis Date: 2021-12-06 Impact factor: 3.090